Skip to main content
Top
Published in: Current Colorectal Cancer Reports 6/2016

01-12-2016 | Localized Colorectal Cancer (RD Kim, Section Editor)

Novel Radiation Approaches for the Treatment of Rectal Cancer: Where Are We Now?

Authors: Nitesh Rana, A. Bapsi Chakravarthy, Lisa A. Kachnic

Published in: Current Colorectal Cancer Reports | Issue 6/2016

Login to get access

Abstract

Over the past decade, significant strides have been made in improving local control for stage II and III rectal cancer, including the use of neoadjuvant chemoradiation and total mesorectal excision. These advancements have led to a remarkable 10-year local failure rate of just 7.1 %. This has come, however, at the cost of moderate treatment-related morbidity, emphasizing a need for further refinement of management strategies. This article will explore recent innovations and novel approaches involving radiation therapy to address these issues, including the use of intensity-modulated radiation therapy, avoidance of radical resection with the use of chemoradiation alone, total neoadjuvant chemotherapy with the selective use of chemoradiation, and the use of local excision approaches following neoadjuvant treatment. Although many of these novel strategies appear promising, data from prospective randomized trials will be necessary before implementation into standard practice.
Literature
1.
go back to reference Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol. 1988;13:245–52.CrossRefPubMed Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol. 1988;13:245–52.CrossRefPubMed
2.
go back to reference Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709–15.CrossRefPubMed Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709–15.CrossRefPubMed
3.
go back to reference Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80:21–9.CrossRefPubMed Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80:21–9.CrossRefPubMed
4.
go back to reference NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–50.CrossRef NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–50.CrossRef
5.
go back to reference Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefPubMed Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefPubMed
6.
go back to reference MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457–60.CrossRefPubMed MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457–60.CrossRefPubMed
7.
go back to reference Martling AL, Holm T, Rutqvist LE, et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet. 2000;356:93–6.CrossRefPubMed Martling AL, Holm T, Rutqvist LE, et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet. 2000;356:93–6.CrossRefPubMed
8.
go back to reference Havenga K, Enker WE, Norstein J, et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol. 1999;25:368–74.CrossRefPubMed Havenga K, Enker WE, Norstein J, et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol. 1999;25:368–74.CrossRefPubMed
9.
go back to reference van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–82.CrossRefPubMed van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–82.CrossRefPubMed
10.
go back to reference Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.CrossRefPubMed Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.CrossRefPubMed
11.
go back to reference Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373:821–8.CrossRefPubMedPubMedCentral Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373:821–8.CrossRefPubMedPubMedCentral
12.
go back to reference Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.CrossRefPubMed Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.CrossRefPubMed
13.
go back to reference Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med. 1985;312:1465–72.CrossRef Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med. 1985;312:1465–72.CrossRef
14.
go back to reference Cedermark B, Johansson H, Rutqvist LE, Wilking N. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer. 1995;75:2269–75.CrossRefPubMed Cedermark B, Johansson H, Rutqvist LE, Wilking N. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer. 1995;75:2269–75.CrossRefPubMed
15.
go back to reference Marijnen CA, van de Velde CJ, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005;23:1847–58.CrossRefPubMed Marijnen CA, van de Velde CJ, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005;23:1847–58.CrossRefPubMed
16.
go back to reference Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199–206.CrossRefPubMed Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199–206.CrossRefPubMed
17.
go back to reference Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum. 1999;42:167–73.CrossRefPubMed Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum. 1999;42:167–73.CrossRefPubMed
18.
go back to reference Merchant NB, Guillem JG, Paty PB, et al. T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg. 1999;3:642–7.CrossRefPubMed Merchant NB, Guillem JG, Paty PB, et al. T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg. 1999;3:642–7.CrossRefPubMed
19.
go back to reference Lopez-Kostner F, Lavery IC, Hool GR, et al. Total mesorectal excision is not necessary for cancers of the upper rectum. Surgery. 1998;124:612–7. discussion 617–8.CrossRefPubMed Lopez-Kostner F, Lavery IC, Hool GR, et al. Total mesorectal excision is not necessary for cancers of the upper rectum. Surgery. 1998;124:612–7. discussion 617–8.CrossRefPubMed
20.
go back to reference Tepper JE, O’Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of Intergroup 0114. J Clin Oncol. 2002;20:1744–50.CrossRefPubMed Tepper JE, O’Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of Intergroup 0114. J Clin Oncol. 2002;20:1744–50.CrossRefPubMed
21.
go back to reference Faerden AE, Naimy N, Wiik P, et al. Total mesorectal excision for rectal cancer: difference in outcome for low and high rectal cancer. Dis Colon Rectum. 2005;48:2224–31.CrossRefPubMed Faerden AE, Naimy N, Wiik P, et al. Total mesorectal excision for rectal cancer: difference in outcome for low and high rectal cancer. Dis Colon Rectum. 2005;48:2224–31.CrossRefPubMed
22.
go back to reference Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004;22:1785–96.CrossRefPubMed Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004;22:1785–96.CrossRefPubMed
23.
go back to reference AJCC. Staging manual. 7th ed. New York: Springer; 2010. AJCC. Staging manual. 7th ed. New York: Springer; 2010.
24.
go back to reference Nissan A, Stojadinovic A, Shia J, et al. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin Oncol. 2006;24:4078–84.CrossRefPubMed Nissan A, Stojadinovic A, Shia J, et al. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin Oncol. 2006;24:4078–84.CrossRefPubMed
25.
go back to reference Simunovic M, Sexton R, Rempel E, et al. Optimal preoperative assessment and surgery for rectal cancer may greatly limit the need for radiotherapy. Br J Surg. 2003;90:999–1003.CrossRefPubMed Simunovic M, Sexton R, Rempel E, et al. Optimal preoperative assessment and surgery for rectal cancer may greatly limit the need for radiotherapy. Br J Surg. 2003;90:999–1003.CrossRefPubMed
26.
go back to reference Chan E, Wise PE, Chakravarthy AB. Controversies in radiation for upper rectal cancers. J Natl Compr Canc Netw. 2012;10:1567–72.PubMed Chan E, Wise PE, Chakravarthy AB. Controversies in radiation for upper rectal cancers. J Natl Compr Canc Netw. 2012;10:1567–72.PubMed
27.•
go back to reference Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513–8. Phase II trial evaluating upfront chemotherapy followed by selective use of chemoradiation. After upfront chemotherapy, responders went on to immediate TME, whereas non-responders went on to preoperative chemoradiation prior to TME. Of 30 patients completing preoperative chemotherapy, all had tumor regression and TME without preoperative chemoradiotherapy. The pathologic complete response rate to chemotherapy alone was 25 %, the 4-year local recurrence rate was 0 %, and the 4-year disease-free survival was 84 %, suggesting that neoadjuvant chemotherapy and selective radiation does not compromise outcomes. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513–8. Phase II trial evaluating upfront chemotherapy followed by selective use of chemoradiation. After upfront chemotherapy, responders went on to immediate TME, whereas non-responders went on to preoperative chemoradiation prior to TME. Of 30 patients completing preoperative chemotherapy, all had tumor regression and TME without preoperative chemoradiotherapy. The pathologic complete response rate to chemotherapy alone was 25 %, the 4-year local recurrence rate was 0 %, and the 4-year disease-free survival was 84 %, suggesting that neoadjuvant chemotherapy and selective radiation does not compromise outcomes.
28.
go back to reference Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184–90.CrossRefPubMed Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184–90.CrossRefPubMed
29.
go back to reference Hayden DM, Pinzon MC, Francescatti AB, et al. Hospital readmission for fluid and electrolyte abnormalities following ileostomy construction: preventable or unpredictable? J Gastrointest Surg. 2013;17:298–303.CrossRefPubMed Hayden DM, Pinzon MC, Francescatti AB, et al. Hospital readmission for fluid and electrolyte abnormalities following ileostomy construction: preventable or unpredictable? J Gastrointest Surg. 2013;17:298–303.CrossRefPubMed
30.•
go back to reference Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†. Ann Oncol. 2015;26:1722–8. Phase II randomized trial from Spain which demonstrated lower toxicity profile, improved chemotherapy compliance, and similar long-term outcomes (5-year OS, DFS, and LR) with total neoadjuvant therapy compared to conventional treatment.CrossRefPubMed Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†. Ann Oncol. 2015;26:1722–8. Phase II randomized trial from Spain which demonstrated lower toxicity profile, improved chemotherapy compliance, and similar long-term outcomes (5-year OS, DFS, and LR) with total neoadjuvant therapy compared to conventional treatment.CrossRefPubMed
31.•
go back to reference Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16:957–66. Phase II trial which demonstrated higher rates of pCR (up to 38 %) with adding mFOLFOX6 after neoadjuvant chemoradiation, without a reported increase in tumor progression or surgical complications. However, this study is limited by its non-randomized nature and lack of long-term follow-up necessary to evaluate disease-specific outcomes. Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16:957–66. Phase II trial which demonstrated higher rates of pCR (up to 38 %) with adding mFOLFOX6 after neoadjuvant chemoradiation, without a reported increase in tumor progression or surgical complications. However, this study is limited by its non-randomized nature and lack of long-term follow-up necessary to evaluate disease-specific outcomes.
32.
go back to reference Kasparek MS, Hassan I, Cima RR, et al. Long-term quality of life and sexual and urinary function after abdominoperineal resection for distal rectal cancer. Dis Colon Rectum. 2012;55:147–54.CrossRefPubMed Kasparek MS, Hassan I, Cima RR, et al. Long-term quality of life and sexual and urinary function after abdominoperineal resection for distal rectal cancer. Dis Colon Rectum. 2012;55:147–54.CrossRefPubMed
33.
go back to reference Camilleri-Brennan J, Steele RJ. Objective assessment of morbidity and quality of life after surgery for low rectal cancer. Colorectal Dis. 2002;4:61–6.CrossRefPubMed Camilleri-Brennan J, Steele RJ. Objective assessment of morbidity and quality of life after surgery for low rectal cancer. Colorectal Dis. 2002;4:61–6.CrossRefPubMed
34.
go back to reference Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.CrossRefPubMed Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.CrossRefPubMed
35.
go back to reference Zorcolo L, Rosman AS, Restivo A, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol. 2012;19:2822–32.CrossRefPubMed Zorcolo L, Rosman AS, Restivo A, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol. 2012;19:2822–32.CrossRefPubMed
36.
go back to reference Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918–28.CrossRefPubMed Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918–28.CrossRefPubMed
37.
go back to reference Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17:174–83.CrossRefPubMed Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17:174–83.CrossRefPubMed
38.
go back to reference Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711–7. discussion 717–8.PubMedPubMedCentral Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711–7. discussion 717–8.PubMedPubMedCentral
39.
go back to reference Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633–40.CrossRefPubMed Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633–40.CrossRefPubMed
40.
go back to reference Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012;256:965–72.CrossRefPubMed Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012;256:965–72.CrossRefPubMed
41.
go back to reference Appelt AL, Pløen J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919–27.CrossRefPubMed Appelt AL, Pløen J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919–27.CrossRefPubMed
42.
go back to reference Habr-Gama A, Gama-Rodrigues J, São Julião GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88:822–8.CrossRefPubMed Habr-Gama A, Gama-Rodrigues J, São Julião GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88:822–8.CrossRefPubMed
43.•
go back to reference Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum. 2013;56:1109–17. Prospective single-institution study evaluating watchful waiting with extended chemoradiation therapy (six cycles of 5-fluorouracil/leucovorin and radiation dose escalation to 54 Gy) and delayed assessment of response (10 weeks). This study demonstrated an initial cCR rate of 68 % and sustained (>12 months) cCR rate of 57 %, thus avoiding immediate radical surgery in a substantial proportion of patients with non-metastatic rectal cancer. Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum. 2013;56:1109–17. Prospective single-institution study evaluating watchful waiting with extended chemoradiation therapy (six cycles of 5-fluorouracil/leucovorin and radiation dose escalation to 54 Gy) and delayed assessment of response (10 weeks). This study demonstrated an initial cCR rate of 68 % and sustained (>12 months) cCR rate of 57 %, thus avoiding immediate radical surgery in a substantial proportion of patients with non-metastatic rectal cancer.
45.
go back to reference Balslev I, Harling H. Sexual dysfunction following operation for carcinoma of the rectum. Dis Colon Rectum. 1983;26:785–8.CrossRefPubMed Balslev I, Harling H. Sexual dysfunction following operation for carcinoma of the rectum. Dis Colon Rectum. 1983;26:785–8.CrossRefPubMed
46.
go back to reference Longo WE, Virgo KS, Johnson FE, et al. Outcome after proctectomy for rectal cancer in Department of Veterans Affairs Hospitals: a report from the National Surgical Quality Improvement Program. Ann Surg. 1998;228:64–70.CrossRefPubMedPubMedCentral Longo WE, Virgo KS, Johnson FE, et al. Outcome after proctectomy for rectal cancer in Department of Veterans Affairs Hospitals: a report from the National Surgical Quality Improvement Program. Ann Surg. 1998;228:64–70.CrossRefPubMedPubMedCentral
47.
go back to reference Neal DE, Williams NS, Johnston D. A prospective study of bladder function before and after sphincter-saving resections for low carcinoma of the rectum. Br J Urol. 1981;53:558–64.CrossRefPubMed Neal DE, Williams NS, Johnston D. A prospective study of bladder function before and after sphincter-saving resections for low carcinoma of the rectum. Br J Urol. 1981;53:558–64.CrossRefPubMed
48.
go back to reference Greenberg JA, Shibata D, Herndon JE, et al. Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Dis Colon Rectum. 2008;51:1185–91. discussion 1191–4.CrossRefPubMed Greenberg JA, Shibata D, Herndon JE, et al. Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Dis Colon Rectum. 2008;51:1185–91. discussion 1191–4.CrossRefPubMed
49.
go back to reference Lezoche E, Baldarelli M, Lezoche G, et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg. 2012;99:1211–8.CrossRefPubMed Lezoche E, Baldarelli M, Lezoche G, et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg. 2012;99:1211–8.CrossRefPubMed
50.•
go back to reference Garcia-Aguilar J, Renfro LA, Chow OS, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015;16:1537–46. Multi-institutional single-arm phase II trial evaluating local excision after neoadjuvant chemoradiotherapy for cT2N0 rectal cancer patients. This study had lower than expected 3-year DFS (86.9 %), but suggests that neoadjuvant chemotherapy plus organ-preserving local excision can be considered in carefully selected cT2N0 rectal cancer patients who refuse, or are not candidates for, radical resection.CrossRefPubMedPubMedCentral Garcia-Aguilar J, Renfro LA, Chow OS, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015;16:1537–46. Multi-institutional single-arm phase II trial evaluating local excision after neoadjuvant chemoradiotherapy for cT2N0 rectal cancer patients. This study had lower than expected 3-year DFS (86.9 %), but suggests that neoadjuvant chemotherapy plus organ-preserving local excision can be considered in carefully selected cT2N0 rectal cancer patients who refuse, or are not candidates for, radical resection.CrossRefPubMedPubMedCentral
51.•
go back to reference Pucciarelli S, De Paoli A, Guerrieri M, et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum. 2013;56:1349–56. Multicenter phase II trial which evaluated local excision in T2/T3 rectal cancer patients who achieve ypT0-1 after neoadjuvant chemoradiotherapy. Early data show promising 3-year OS, DFS, and local control. Pucciarelli S, De Paoli A, Guerrieri M, et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum. 2013;56:1349–56. Multicenter phase II trial which evaluated local excision in T2/T3 rectal cancer patients who achieve ypT0-1 after neoadjuvant chemoradiotherapy. Early data show promising 3-year OS, DFS, and local control.
52.
go back to reference Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27–33.CrossRefPubMed Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27–33.CrossRefPubMed
53.
go back to reference Parekh A, Truong MT, Pashtan I, et al. Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer. Gastrointest Cancer Res. 2013;6:137–43.PubMedPubMedCentral Parekh A, Truong MT, Pashtan I, et al. Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer. Gastrointest Cancer Res. 2013;6:137–43.PubMedPubMedCentral
54.•
go back to reference Engels B, Platteaux N, Van den Begin R, et al. Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome. Radiother Oncol. 2014;110:155–9. Prospective phase II study exploring IMRT with SIB in rectal cancer patients. This study showed excellent 5-year LC of 97 % with a 13 % rate of any grade ≥3 toxicity. Engels B, Platteaux N, Van den Begin R, et al. Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome. Radiother Oncol. 2014;110:155–9. Prospective phase II study exploring IMRT with SIB in rectal cancer patients. This study showed excellent 5-year LC of 97 % with a 13 % rate of any grade ≥3 toxicity.
55.
go back to reference Jabbour SK, Patel S, Herman JM, et al. Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits. Int J Surg Oncol. 2012;2012:891067.PubMedPubMedCentral Jabbour SK, Patel S, Herman JM, et al. Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits. Int J Surg Oncol. 2012;2012:891067.PubMedPubMedCentral
56.
go back to reference Samuelian JM, Callister MD, Ashman JB, et al. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82:1981–7.CrossRefPubMed Samuelian JM, Callister MD, Ashman JB, et al. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82:1981–7.CrossRefPubMed
57.
go back to reference Zhu J, Liu F, Gu W, et al. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Radiat Oncol. 2014;9:70.CrossRefPubMedPubMedCentral Zhu J, Liu F, Gu W, et al. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Radiat Oncol. 2014;9:70.CrossRefPubMedPubMedCentral
58.
go back to reference Arbea L, Martínez-Monge R, Díaz-González JA, et al. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. Int J Radiat Oncol Biol Phys. 2012;83:587–93.CrossRefPubMed Arbea L, Martínez-Monge R, Díaz-González JA, et al. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. Int J Radiat Oncol Biol Phys. 2012;83:587–93.CrossRefPubMed
59.
go back to reference Zhao J, Hu W, Cai G, et al. Dosimetric comparisons of VMAT, IMRT and 3DCRT for locally advanced rectal cancer with simultaneous integrated boost. Oncotarget. 2016;7:6345–51.PubMed Zhao J, Hu W, Cai G, et al. Dosimetric comparisons of VMAT, IMRT and 3DCRT for locally advanced rectal cancer with simultaneous integrated boost. Oncotarget. 2016;7:6345–51.PubMed
60.
go back to reference Guerrero Urbano MT, Henrys AJ, Adams EJ, et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys. 2006;65:907–16.CrossRefPubMed Guerrero Urbano MT, Henrys AJ, Adams EJ, et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys. 2006;65:907–16.CrossRefPubMed
61.•
go back to reference Hong TS, Moughan J, Garofalo MC, et al. NRG Oncology Radiation Therapy Oncology Group 0822: a phase 2 study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2015;93:29–36. Phase II trial designed to evaluate the rate of GI toxicity with preoperative IMRT and concurrent capecitabine/oxaliplatin. This study used historical data for comparison (preoperative 3D-CRT with concurrent capecitabine/oxaliplatin arm from RTOG 0247) and failed to show reduction in GI toxicity with IMRT. However, the high rate of GI toxicity is likely due to the use of concurrent oxaliplatin. Hong TS, Moughan J, Garofalo MC, et al. NRG Oncology Radiation Therapy Oncology Group 0822: a phase 2 study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2015;93:29–36. Phase II trial designed to evaluate the rate of GI toxicity with preoperative IMRT and concurrent capecitabine/oxaliplatin. This study used historical data for comparison (preoperative 3D-CRT with concurrent capecitabine/oxaliplatin arm from RTOG 0247) and failed to show reduction in GI toxicity with IMRT. However, the high rate of GI toxicity is likely due to the use of concurrent oxaliplatin.
62.
go back to reference Wong SJ, Winter K, Meropol NJ, et al. Radiation Therapy Oncology Group 0247: a randomized phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82:1367–75.CrossRefPubMed Wong SJ, Winter K, Meropol NJ, et al. Radiation Therapy Oncology Group 0247: a randomized phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82:1367–75.CrossRefPubMed
63.••
go back to reference O’Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927–34. Large phase III trial which compared four chemotherapy regimens administered concomitantly with preoperative radiation. This study demonstrated that the addition of oxaliplatin to capecitabine and radiation did not improve surgical outcomes, but added significant toxicity. O’Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927–34. Large phase III trial which compared four chemotherapy regimens administered concomitantly with preoperative radiation. This study demonstrated that the addition of oxaliplatin to capecitabine and radiation did not improve surgical outcomes, but added significant toxicity.
Metadata
Title
Novel Radiation Approaches for the Treatment of Rectal Cancer: Where Are We Now?
Authors
Nitesh Rana
A. Bapsi Chakravarthy
Lisa A. Kachnic
Publication date
01-12-2016
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 6/2016
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-016-0337-2

Other articles of this Issue 6/2016

Current Colorectal Cancer Reports 6/2016 Go to the issue

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

Adjuvant Chemotherapy for Colon Cancer: Guidelines and Clinical Trials in Japan

Prevention and Early Detection (R Benamouzig, Section Editor)

What Is the Best Approach to Avoid Colorectal Cancer Risk in Inflammatory Bowel Disease?

Molecular Epidemiology (L Jiao and CR Daniel-MacDougall, Section Editors)

Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

Molecular Classification of Colon Cancer: Perspectives for Personalized Adjuvant Therapy

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

Ongoing Adjuvant/Neoadjuvant Trials in Resectable Metastatic Colorectal Cancer

Localized Colorectal Cancer (RD Kim, Section Editor)

The Role of Adjuvant Treatment in Resected T3N0 Rectal Cancer

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine